- Home
- SOAR vs CMMB Comparison
SOAR vs CMMB Comparison
Compare SOAR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- CMMB
- Stock Information
- Founded
- SOAR 2021
- CMMB 2004
- Country
- SOAR United States
- CMMB Israel
- Employees
- SOAR N/A
- CMMB N/A
- Industry
- SOAR Blank Checks
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SOAR Finance
- CMMB Health Care
- Exchange
- SOAR Nasdaq
- CMMB Nasdaq
- Market Cap
- SOAR 15.7M
- CMMB 13.7M
- IPO Year
- SOAR N/A
- CMMB N/A
- Fundamental
- Price
- SOAR $1.40
- CMMB $2.67
- Analyst Decision
- SOAR
- CMMB Strong Buy
- Analyst Count
- SOAR 0
- CMMB 2
- Target Price
- SOAR N/A
- CMMB $26.50
- AVG Volume (30 Days)
- SOAR 1.4M
- CMMB 125.7K
- Earning Date
- SOAR 11-18-2025
- CMMB 11-12-2025
- Dividend Yield
- SOAR N/A
- CMMB N/A
- EPS Growth
- SOAR N/A
- CMMB N/A
- EPS
- SOAR N/A
- CMMB N/A
- Revenue
- SOAR $96,397,000.00
- CMMB N/A
- Revenue This Year
- SOAR N/A
- CMMB N/A
- Revenue Next Year
- SOAR N/A
- CMMB N/A
- P/E Ratio
- SOAR N/A
- CMMB N/A
- Revenue Growth
- SOAR 309.80
- CMMB N/A
- 52 Week Low
- SOAR $1.14
- CMMB $2.39
- 52 Week High
- SOAR $19.06
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- SOAR 38.78
- CMMB 43.15
- Support Level
- SOAR $1.25
- CMMB $2.51
- Resistance Level
- SOAR $1.73
- CMMB $2.80
- Average True Range (ATR)
- SOAR 0.19
- CMMB 0.20
- MACD
- SOAR -0.07
- CMMB -0.06
- Stochastic Oscillator
- SOAR 14.57
- CMMB 21.39
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.